echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Neurology: Biomarkers for the detection of atrial fibrillation after stroke: a systematic review and meta-analysis

    Neurology: Biomarkers for the detection of atrial fibrillation after stroke: a systematic review and meta-analysis

    • Last Update: 2021-09-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cardiac infarction, atrial fibrillation is usually caused by (AF) caused, resulting in about 1/3 of the ischemic brain stroke occurs, can cause serious stroke
    .


    Anticoagulation is very effective in reducing the risk of stroke in patients with AF.


    Stroke

    Long-term heart monitoring can help detect more atrial fibrillation
    .


    Wearing a ring recorder for 30 days can detect atrial fibrillation in 16.


    Recently, researchers have used systematic reviews and meta-analysis to determine clinical, electrocardiogram, and blood biomarkers related to AF detection one year after ischemic stroke/TIA


    • Variables associated with an increased likelihood of atrial fibrillation were age (OR 3.
      26, 95%CI 2.
      354.
      54), female (OR 1.
      47, 95%CI 1.
      23-1.
      77), and history of heart failure (OR 2.
      56, 95%CI 1.
      87-3.
      49) ), hypertension (OR 1.
      42, 95%CI 1.
      15-1.
      75) or ischemic heart disease (OR 1.
      80, 95%CI 1.
      34-2.
      42), higher modified Rankin classification (OR 6.
      13, 95%CI 2.
      93~12.
      84) Or the National Institutes of Health Stroke Scale score (OR 2.
      50, 95%CI 1.
      64~3.
      81), no obvious carotid artery/intracranial artery stenosis (OR 3.
      23, 95%CI 1.
      14~9.
      11), non-smoker (OR 1.
      93, 95 %CI 1.
      48~2.
      51), statin therapy (OR 2.
      07, 95%CI 1.
      143.
      73), stroke as an indicator diagnosis (OR 1.
      59, 95%CI 1.
      17~2.
      18), systolic blood pressure (OR 1.
      61, 95%CI 1.
      16- 2.
      22), intravenous thrombolysis (OR 2.
      40, 95%CI 1.
      83-3.
      16), atrioventricular block (OR 2.
      12, 95%CI 1.
      08-4.
      17), left ventricular hypertrophy (OR 2.
      21, 95%CI 1.
      03-4.
      74) , Atrial premature beats (OR 3.
      90, 95%CI 1.
      74-8.
      74), maximum P wave duration (OR 3.
      19, 95%CI 1.
      40-7.
      25), PR interval (OR 2.
      32, 95%CI 1.
      11-4.
      83), P wave dispersion Degree (OR 7.
      79, 95%CI 4.
      16-14.
      61), P wave index (OR 3.
      44, 95%CI 1.
      87-6.
      32), QTc interval (OR 3.
      68, 95%CI 1.
      63-8.
      28), brain natriuretic peptide (OR 13.
      73 , 95% CI 3.
      31-57.
      07) and high-density lipoprotein cholesterol (OR 1.
      49 , 95% CI 1.
      171.
      88) concentration
      .
    • Variables associated with reduced likelihood are minimum P wave duration (OR 0.
      53, 95% CI 0.
      290.
      98), LDL-cholesterol (OR 0.
      73, 95% CI 0.
      57-0.
      93) and triglycerides (OR 0.
      51, 95% CI 0.
      41-0.
      64) Concentration
      .
  • Variables associated with an increased likelihood of atrial fibrillation were age (OR 3.
    26, 95%CI 2.
    354.
    54), female (OR 1.
    47, 95%CI 1.
    23-1.
    77), and history of heart failure (OR 2.
    56, 95%CI 1.
    87-3.
    49) ), hypertension (OR 1.
    42, 95%CI 1.
    15-1.
    75) or ischemic heart disease (OR 1.
    80, 95%CI 1.
    34-2.
    42), higher modified Rankin classification (OR 6.
    13, 95%CI 2.
    93~12.
    84) Or the National Institutes of Health Stroke Scale score (OR 2.
    50, 95%CI 1.
    64~3.
    81), no obvious carotid artery/intracranial artery stenosis (OR 3.
    23, 95%CI 1.
    14~9.
    11), non-smoker (OR 1.
    93, 95 %CI 1.
    48~2.
    51), statin therapy (OR 2.
    07, 95%CI 1.
    143.
    73), stroke as an indicator diagnosis (OR 1.
    59, 95%CI 1.
    17~2.
    18), systolic blood pressure (OR 1.
    61, 95%CI 1.
    16- 2.
    22), intravenous thrombolysis (OR 2.
    40, 95%CI 1.
    83-3.
    16), atrioventricular block (OR 2.
    12, 95%CI 1.
    08-4.
    17), left ventricular hypertrophy (OR 2.
    21, 95%CI 1.
    03-4.
    74) , Atrial premature beats (OR 3.
    90, 95%CI 1.
    74-8.
    74), maximum P wave duration (OR 3.
    19, 95%CI 1.
    40-7.
    25), PR interval (OR 2.
    32, 95%CI 1.
    11-4.
    83), P wave dispersion Degree (OR 7.
    79, 95%CI 4.
    16-14.
    61), P wave index (OR 3.
    44, 95%CI 1.
    87-6.
    32), QTc interval (OR 3.
    68, 95%CI 1.
    63-8.
    28), brain natriuretic peptide (OR 13.
    73 , 95% CI 3.
    31-57.
    07) and high-density lipoprotein cholesterol (OR 1.
    49 , 95% CI 1.
    171.
    88) concentration
    .
  • Age (OR 3.
    26, 95%CI 2.
    354.
    54), female (OR 1.
    47, 95%CI 1.
    23-1.
    77), history of heart failure (OR 2.
    56, 95%CI 1.
    87-3.
    49), hypertension (OR 1.
    42, 95%CI 1.
    15-1.
    75) or ischemic heart disease (OR 1.
    80, 95%CI 1.
    34-2.
    42), higher modified Rankin classification (OR 6.
    13, 95%CI 2.
    93-12.
    84) or National Institutes of Health Stroke Scale score ( OR 2.
    50, 95%CI 1.
    64~3.
    81), no obvious carotid artery/intracranial artery stenosis (OR 3.
    23, 95%CI 1.
    14~9.
    11), non-smoker (OR 1.
    93, 95%CI 1.
    48~2.
    51), statin therapy (OR 2.
    07, 95%CI 1.
    143.
    73), stroke as the index diagnosis (OR 1.
    59, 95%CI 1.
    17~2.
    18), systolic blood pressure (OR 1.
    61, 95%CI 1.
    16-2.
    22), intravenous thrombolytic therapy (OR 2.
    40, 95%CI 1.
    83-3.
    16), atrioventricular block (OR 2.
    12, 95%CI 1.
    08-4.
    17), left ventricular hypertrophy (OR 2.
    21, 95%CI 1.
    03-4.
    74), atrial premature beats (OR 3.
    90, 95%CI 1.
    74-8.
    74), maximum P wave time limit (OR 3.
    19, 95%CI 1.
    40-7.
    25), PR interval (OR 2.
    32, 95%CI 1.
    11-4.
    83), P wave dispersion (OR 7.
    79, 95%CI 4.
    16-14.
    61) ), P wave index (OR 3.
    44, 95%CI 1.
    87-6.
    32), QTc interval (OR 3.
    68, 95%CI 1.
    63-8.
    28), brain natriuretic peptide (OR 13.
    73, 95%CI 3.
    31-57.
    07) and high density Lipoprotein cholesterol (OR 1.
    49, 95% CI 1.
    171.
    88) concentration to diagnose cholesterol
  • Variables associated with reduced likelihood are minimum P wave duration (OR 0.
    53, 95% CI 0.
    290.
    98), LDL-cholesterol (OR 0.
    73, 95% CI 0.
    57-0.
    93) and triglycerides (OR 0.
    51, 95% CI 0.
    41-0.
    64) Concentration
    .
  • Minimum P wave duration (OR 0.
    53, 95% CI 0.
    290.
    98), LDL-cholesterol (OR 0.
    73, 95% CI 0.
    57-0.
    93) and triglyceride (OR 0.
    51, 95% CI 0.
    41-0.
    64) concentration
    .


          The study identified multimodal biomarkers that can help guide patient selection for cardiac monitoring after ischemic stroke/transient ischemic attack (TIA)
    .


    Their prognostic utility should be prospectively evaluated based on the results of atrial fibrillation detection and recurrent stroke


    The study identified multimodal biomarkers that can help guide patient selection for cardiac monitoring after ischemic stroke/transient ischemic attack (TIA)


    https://n.
    neurology.
    org/content/early/2021/09/09/WNL.
    0000000000012769.
    long Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.